POSA126 An Economic Analysis of Empagliflozin Versus Sacubitril/Valsartan in Patients with Heart Failure with Reduced Ejection Fraction (HFREF) in the United Kingdom (UK)

O Reifsnider,A Tafazzoli, L Bellanca, M Litkiewicz, M Stargardter, S Linden

Value in Health（2022）

引用 0|浏览3

暂无评分

摘要

To conduct a cost-minimization analysis of empagliflozin versus sacubitril/valsartan in HFrEF patients who were already treated with standard of care (SoC) including ACEi/ARB, beta blockers, MRAs, and/or ivabradine.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要